Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Dec 28;23(1):295.
doi: 10.3390/ijms23010295.

Circulating Nucleic Acid-Based Biomarkers of Type 2 Diabetes

Felipe Padilla-Martinez  1 , Gladys Wojciechowska  1 , Lukasz Szczerbinski  1   2 , Adam Kretowski  1   2
Affiliations
Review

Circulating Nucleic Acid-Based Biomarkers of Type 2 Diabetes

Felipe Padilla-Martinez et al. Int J Mol Sci. .

Abstract

Type 2 diabetes (T2D) is a deficiency in how the body regulates glucose. Uncontrolled T2D will result in chronic high blood sugar levels, eventually resulting in T2D complications. These complications, such as kidney, eye, and nerve damage, are even harder to treat. Identifying individuals at high risk of developing T2D and its complications is essential for early prevention and treatment. Numerous studies have been done to identify biomarkers for T2D diagnosis and prognosis. This review focuses on recent T2D biomarker studies based on circulating nucleic acids using different omics technologies: genomics, transcriptomics, and epigenomics. Omics studies have profiled biomarker candidates from blood, urine, and other non-invasive samples. Despite methodological differences, several candidate biomarkers were reported for the risk and diagnosis of T2D, the prognosis of T2D complications, and pharmacodynamics of T2D treatments. Future studies should be done to validate the findings in larger samples and blood-based biomarkers in non-invasive samples to support the realization of precision medicine for T2D.

Keywords: biomarkers; epigenomics; genomics; nucleic acid; transcriptomics; type 2 diabetes.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Khan M.A.B., Hashim M.J., King J.K., Govender R.D., Mustafa H., Al Kaabi J. Epidemiology of Type 2 Diabetes—Global Burden of Disease and Forecasted Trends. J. Epidemiol. Glob. Health. 2020;10:107–111. doi: 10.2991/jegh.k.191028.001. - DOI - PMC - PubMed
    1. Herman W.H., Ye W., Griffin S.J., Simmons R.K., Davies M.J., Khunti K., Rutten G.E.H.M., Sandbaek A., Lauritzen T., Borch-Johnsen K., et al. Early Detection and Treatment of Type 2 Diabetes Reduce Cardiovascular Morbidity and Mortality: A Simulation of the Results of the Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care (ADDITION-Europe) Diabetes Care. 2015;38:1449–1455. doi: 10.2337/dc14-2459. - DOI - PMC - PubMed
    1. American Diabetes Association 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021;44((Suppl. S1)):S15–S33. doi: 10.2337/dc21-S002. - DOI - PubMed
    1. Harris M.I., Eastman R.C. Early Detection of Undiagnosed Diabetes Mellitus: A US Perspective. Diabetes Metab. Res. Rev. 2000;16:230–236. doi: 10.1002/1520-7560(2000)9999:9999<::AID-DMRR122>3.0.CO;2-W. - DOI - PubMed
    1. Inzucchi S.E., Bergenstal R.M., Buse J.B., Diamant M., Ferrannini E., Nauck M., Peters A.L., Tsapas A., Wender R., Matthews D.R. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140–149. doi: 10.2337/dc14-2441. - DOI - PubMed

Grants and funding